AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma
Status:
Completed
Trial end date:
2017-01-07
Target enrollment:
Participant gender:
Summary
RATIONALE: AR-42 may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of AR-42 in treating
patients with advanced or relapsed multiple myeloma, chronic lymphocytic leukemia, or
lymphoma.